Aerosolized Agents for Airway Clearance in Cystic Fibrosis: When, how and why? A roundtable discussion

This activity is presented as a roundtable discussion between three international expert faculty in cystic fibrosis (CF). This expert faculty will discuss the role of aerosolized agents for improving airway clearance, including caveats from their own extensive clinical experience in managing patients with this condition. The faculty will also deliberate on strategies to improve patient adherence to CF therapy in a case study based format. These discussions will support participants in clinical decision making as well as in helping their patients achieve optimal benefit through adherence to their CF therapy.


This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with cystic fibrosis.


At the conclusion of the roundtable discussion:

KNOWLEDGE: Participants will self-report knowledge gain of scientific evidence and guideline recommendations for CF management and strategies for improving treatment adherence in CF.

COMPETENCE/SKILL: Participants will self-report intent to change practice by applying best practices for CF management and using strategies to promote adherence to CF therapies.


Upon completion of this activity, participants will be able to:

  1. Discuss the mechanisms of action of, clinical evidence for, and appropriate use of pharmacologic agents for lung clearance in CF.
  2. Analyze the guideline recommendations on the use of pharmacologic lung clearance agents in CF.
  3. Educate patients on the direct relationship between adherence to medications and improved outcomes in CF.
  4. Apply communication strategies that will enable the HCPs to be positive drivers to medication adherence in CF.
  5. Incorporate strategies to educate patients on the importance of adherence to medications in CF.


John P. Clancy, MD (Chair)
Gunnar Esiasion/Cincinnati Endowed Chair
Pulmonary Medicine Research Director
Medical Director for the Office of Clinical and Translational Research, Cincinnati
Children’s Hospital Medical Center, Cincinnati, Ohio, USA

Kevin W. Southern, MBChB, MRCP, FRCPCH, PhD
Professor of Child Health
University of Liverpool
Liverpool, United Kingdom

Sarath Ranganathan, MBChB, FRCPCH, FRACP, PhD
Director of Respiratory and Sleep Medicine
Royal Children's Hospital
Melbourne, Australia

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education and Elsevier that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
Professor John P. Clancy, MD (Chair)

Contracted research with Vertex Pharmaceuticals Incorporated, Pro QR Therapeutics, Bayer AG, Concert Pharmaceuticals and Nivalis Therapeutics

Speaker for Genentech, Inc

Grant reviewer for Gilead

Professor Kevin W. Southern, MBChB, MRCP, FRCPCH, PhD

No relationships to disclose

Associate Professor Sarath Ranganathan, MBChB, FRCPCH, FRACP, PhDNo relationships to disclose

Non-faculty: Lisa G. Sullivan; Shilpa Mudgal; Yulyana; Marilu Kelly, MSN, RN, CNE; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from F.Hoffman-La Roche Ltd.


Jointly provided by the Elsevier Office of Continuing Medical Education, Elsevier and In Vivo Academy Limited


The Elsevier Office of Continuing Medical Education (EOCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.

EOCME designates this activity for a maximum of 1.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

An application has been made to the EACCME®.


This continuing nursing education activity, provided by Elsevier, awards 1.5 contact hours for nurses. Elsevier is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Centerʼs Commission on Accreditation (ANCC COA). Elsevier is the provider approved by the Florida Board of Nursing, Provider #50-4681, and the California Board of Registered Nursing, Provider #CEP 3257.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of EOCME, Elsevier, and In Vivo Academy Limited. EOCME is accredited by the ACCME to provide continuing medical education for physicians. Elsevier is accredited by ANCC COA to provide continuing nursing education.


For all CME inquiries or special needs, please contact

For all CNE inquiries or special needs, please contact

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Elsevier and In Vivo Academy Limited, and F.Hoffman-La Roche do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit(s)™
  • 1.50 Nursing Contact Hours
  • 1.50 Non-physician
Course opens: 
Course expires: 

Available Credit

  • 1.50 AMA PRA Category 1 Credit(s)™
  • 1.50 Nursing Contact Hours
  • 1.50 Non-physician
Please login or register to take this course.